Skip to main content
NewslettersWatchlist

Medicure Inc(MPH-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low1.020
Day High1.100
Open:1.100
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Medicure Inc down on Thursday (MPH)
ACCESSWIRE
Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes
ACCESSWIRE
Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
ACCESSWIRE
Medicure Reports Financial Results for Quarter Ended September 30, 2023
AI-generated - The Globe and Mail
Medicure: Top 10 Undervalued Drug Manufacturers Industry Stocks (MPH)
ACCESSWIRE
Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin (Zypitamag) to People Living With HIV
ACCESSWIRE
Medicure Reports Financial Results For Quarter Ended June 30, 2023
ACCESSWIRE
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
The Globe and Mail
Medicure: Top 10 Undervalued Drug Manufacturers Industry Stocks (MPH)
ACCESSWIRE
Medicure Reports Financial Results for Quarter Ended March 31, 2023
ACCESSWIRE
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2022
ACCESSWIRE
Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022
The Globe and Mail
Medicure: Top 10 Undervalued Drug Manufacturers Industry Stocks (MPH)
Newswire.ca
MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS
Newswire.ca
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022
PR Newswire
MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022
PR Newswire
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022
PR Newswire
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022
Newswire.ca
MEDICURE ANNOUNCES RESULTS OF 2022 AGM
Newswire.ca
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2021
Newswire.ca
MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST
Canada Newswire
Medicure Q2 2020 Results and Conference Call Dates
Canada Newswire
Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG™ (Pitavastatin) Tablets
Canada Newswire
C-Suite At The Open: Albert Friessen, Chair & CEO from Medicure Inc. tells his Company story. Filmed May 2020.

Profile

Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.